Yinghao Zhu

Yinghao Zhu

Auto-generated profile, based on publicly available information

Yinghao Zhu


Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2026 in Pain Research and Management
Verified
Journal Article
Open access
YZYinghao Zhu
Yinghao Zhu
HLHao Lv
Hao Lv
YWYi Wang
Yi Wang
XYXunlu Yin
Xunlu Yin
KLKaiming Li
Kaiming Li
LLLong Liang
Long Liang
Background: Lumbar disc herniation (LDH) is a leading cause of chronic low back pain (LBP), severely impairing patients’ quality of life and imposing a substantial global socioeconomic burden. Conservative treatment remains the first‐line clinical option, but the commonly prescribed drug celecoxib carries a risk of gastrointestinal bleeding or perforation. Traditional Chinese medicine preparations have been proposed as alternatives, although current evidence is insufficient. Jintiange (JTG) capsule, developed as a substitute for tiger bone, exerts its pharmacological effects by inhibiting osteoclastogenesis and regulating the NF‐κB pathway. Previous studies have identified a close association between the p38MAPK/NF‐κB pathway and pain induced by LDH. However, the efficacy of JTG in treating LDH remains unclear. High‐quality research is thus urgently needed to provide evidence‐based support for its clinical application. Method: This randomized, single‐center clinical trial will enroll 68 participants, centrally allocated 1:1 to receive either JTG capsules plus comprehensive Western medicine (celecoxib + eperisone) or Western medicine alone. All participants will complete an 8‐week treatment phase (celecoxib for 2 weeks + eperisone for 8 weeks; with JTG capsules added for 8 weeks in the experimental group), with a follow‐up at Week 12 (4 weeks after treatment completion). The primary outcome is the change in the Japanese Orthopaedic Association (JOA) score for LBP, a validated instrument for evaluating treatment efficacy in LDH. Secondary outcomes include the Patient Global Impression of Change (PGIC), Visual Analog Scale (VAS) score, SF‐12 quality‐of‐life score, and elastic modulus of the lumbar muscles. Safety monitoring and adverse‐event recording will occur throughout the study. The primary endpoint will be analyzed using the analysis of covariance. Longitudinal VAS scores at Weeks 2, 8, and 12 will be analyzed using a mixed model for repeated measures. PGIC will be analyzed as an ordinal categorical outcome, while other secondary outcomes will be analyzed using appropriate parametric or nonparametric methods. All analyses will be performed using SPSS 28.0, with no interim analysis planned. Discussion: This trial will evaluate the clinical efficacy of JTG capsules combined with Western medicine for LBP and will explore its safety profile as a secondary/exploratory endpoint. Given the open‐label combination design, safety findings will be interpreted with caution, and causality attribution to JTG alone will be limited. The findings are expected to provide an evidence‐based treatment option, supporting the potential role of Chinese patent medicine in LBP management. Trial Registration: Chinese Registry of Clinical Trials: ChiCTR2300069735

1 January 2026 in Stem Cells International
Verified
Journal Article
Open access
PDF file
HLHao Lv
Hao Lv
HYHairu Yi
Hairu Yi
YZYinghao Zhu
Yinghao Zhu
YWYan Wang
Yan Wang
YYYuxiang Yang
Yuxiang Yang
TJTing Jiang
Ting Jiang
Background: The imbalance between osteogenic and adipogenic differentiation of bone marrow mesenchymal stem cells (BMSCs) is a key factor in osteoporosis (OP). TRIB3 acts as a molecular switch regulating this process. While E3 ubiquitin ligases are known to influence TRIB3 protein stability, the specific role of E3 ligase‐mediated TRIB3 ubiquitination in directing BMSCs’ fate remains unclear. This study systematically investigates this mechanism. Methods: We first predicted potential E3 ubiquitin ligases for TRIB3 using the UbiBrowser database. Differentially expressed E3 ligases were then screened from the GEO datasets. Molecular docking with the TRIB3 protein identified the candidate with the highest binding affinity for a mechanistic study. Serum samples from osteoporotic patients and healthy controls were analyzed to verify clinical correlation. For in vivo validation, we performed in vivo rescue experiments in naturally aged osteoporotic mice using femoral injection of SIAH1‐knockdown lentivirus. Immunohistochemistry, immunofluorescence, and western blot were used to assess the expression of TRIB3 and SIAH1. In vitro, we overexpressed or knocked down SIAH1 to examine its effects on TRIB3 ubiquitination, protein stability, and BMSCs differentiation. TRIB3 rescue assays were performed to confirm the dependency. Results: UbiBrowser analysis identified eight E3 ubiquitin ligases targeting TRIB3. Subsequent screening selected SIAH1 for mechanistic investigation. In aged osteoporotic mice and osteoporotic patients, SIAH1 expression was significantly increased, while TRIB3 was decreased. In vivo rescue experiments showed that local knockdown of SIAH1 restored TRIB3 expression, improved bone mineral density (BMD), trabecular microarchitecture, and rebalanced osteogenic and adipogenic differentiation. In vitro, upregulating SIAH1 promoted TRIB3 ubiquitination and proteasomal degradation, reducing TRIB3 protein levels, downregulating osteogenic markers, and upregulating adipogenic markers. Knocking down SIAH1 yielded the opposite effects. TRIB3 overexpression or knockdown fully reversed the effects of SIAH1 on BMSC differentiation. Conclusion: SIAH1 promotes the ubiquitination and proteasomal degradation of TRIB3, thereby disrupting the osteogenic–adipogenic balance of BMSCs and contributing to age‐related bone loss. Local inhibition of SIAH1 stabilizes TRIB3 and ameliorates OP. These findings provide a scientific basis and novel therapeutic target for regulating BMSCs differentiation and treating age‐related OP via the SIAH1–TRIB3 axis.